Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Capecitabine in Advanced Malignancies
NCT02915172Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2016
- Primary completion
- Dec 2022
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in cancer, breast cancer and solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 3 weeks. Planned start Dec 2016; status: withdrawn.
02
Drugs
lenvatinib
03
Conditions
cancerbreast cancersolid tumor
Beyond the preview
Go deeper on NCT02915172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915172.